Ketamine in Treatment-Resistant Depression: Response Versus Recovery
In this video, Dr Sanil Rege, consultant psychiatrist, reviews the KARMA-Dep 2 trial and examines ketamine in treatment-resistant depression through the lens of response versus recovery, highlighting why early symptom improvement does not necessarily translate into sustained functional change.
Drawing on trial data and response curves, Dr Rege explains the familiar early “wow effect” seen with rapid-acting interventions and why symptom scores often plateau despite initial improvement. The video explores how symptom-based outcome measures may overestimate recovery while underrepresenting persistent impairments in cognition, motivation, and functional capacity.
From a neurobiological perspective, ketamine is framed as a transient plasticity opener rather than a standalone antidepressant. Sustained recovery is described as a separate phase requiring neuroadaptation, environmental change, and structured therapeutic scaffolding. This analysis provides clinicians with a practical framework for interpreting ketamine trial data and integrating rapid-acting treatments into recovery-oriented psychiatric care.
Enhance Your Psychiatry Practice
Join The Academy by Psych Scene and earn CME & CPD points from 150+ hours of expert-led psychiatry courses. Hub Pro Included ✅
Check out our courses
KEY TAKEAWAYS
- Rapid symptom reduction following ketamine is common but does not reliably predict long-term recovery.
- The neurobiology of response differs from the neurobiology of recovery, which requires consolidation and neuroadaptation.
- Symptom rating scales capture short-term change but poorly reflect cognition, motivation, and functional outcomes.
- Inpatient admission itself contributes substantially to early improvement through containment and structure.
- Ketamine may open a window for change, but durable benefit depends on behavioural, psychological, and environmental integration.
To build on the clinical and neurobiological concepts discussed in this video, clinicians may find value in the Clinical Audit on Cognitive Aspects of Depression on The Academy by Psych Scene. This course examines how residual cognitive symptoms contribute to functional impairment in depression and provides a framework for measuring outcomes beyond symptom severity.
Clinicians may also benefit from The Aggregation of Marginal Gains in Psychiatry, led by Prof Michael Berk. This program explores how sustained recovery emerges from the cumulative effect of multiple small interventions across biological, psychological, and social domains — an approach directly relevant to integrating rapid-acting treatments such as ketamine into longitudinal care.
Subscribe to The Academy by Psych Scene on YouTube for clinician-focused videos on psychiatry, neuroscience, and evidence-based clinical practice.
Related Articles & Videos:
- Neurobiology of Depression – A Simplified Guide
- Neuroinflammation in Psychiatry Simplified – The Link Between the Immune System and The Brain- Dr Sanil Rege
- Autoimmune Diseases Masquerading as Psychiatric Disorders – A Paradigm Shift
- A Summary of 3 Important Autoimmune Neuropsychiatric Disorders for Psychiatrists – Dr Sanil Rege
Get Serious About Psychiatry Learning
Our courses offer practical knowledge and clinical expertise at exceptional value, plus CME & CPD points.
Go to Academy by Psych Scene